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Hodgkin’s lymphoma is a hematolymphoid neoplasm, primarily of B cell lineage, that has unique histologic, immunophenotypic,
and clinical features. Neurologic complications of Hodgkin’s Lymphoma can be separated into those that result directly from
the disease, indirectly from the disease, or from its treatment. Direct neurologic dysfunction from Hodgkin’s Lymphoma results
from metastatic intracranial spinal disease, epidural metastases causing spinal cord/cauda equina compression, leptomeningeal
metastases, or intradural intramedullary spinal cord metastases. Indirect neurologic dysfunction may be caused by paraneoplastic
disorders(suchasparaneoplasticcerebellardegenerationorlimbicencephalitis)andprimaryangiitisofthecentralnervoussystem.
Hodgkin’s lymphoma treatment typically includes chemotherapy or radiotherapy with potential treatment-related complications
aﬀecting the nervous system. Neurologic complications resulting from mantle-ﬁeld radiotherapy include the “dropped head
syndrome,” acute brachial plexopathy, and transient ischemic attacks/cerebral infarcts. Chemotherapy for Hodgkin’s lymphoma
may cause cerebral infarction (due to emboli from anthracycline-induced cardiomyopathy) and peripheral neuropathy.
1.Introduction
Hodgkin’s lymphoma (HL) (previously termed Hodgkin’s
disease) is a hematolymphoid neoplasm, primarily of B cell
linage, that has unique histologic, immunophenotypic, and
clinical features. Its incidence is estimated to be 7400 cases
per year in the United States [1]. The age distribution is
bimodal; the ﬁrst peak occurs between the ages of 15 and
30 years and the second in the sixth decade. Staging of the
disease is classiﬁed according to the Cotswold scheme [2].
Treatment is based on disease stage and prognostic factors
independent of stage such as bulky disease [1]. Treatment
is usually multiagent chemotherapy, most often utilizing
doxorubicin,bleomycin,vinblastine,anddacarbazine,radio-
therapy (RT), or both.
Although neurologic complications from HL or its
treatment are rare, there are several unique disorders that
may be seen and are clinically recognizable (Algorithm 1).
The neurologic disorders related to HL can be separated into
those that result directly from HL, that is, metastatic compli-
cations, indirectly from HL, or from HL-directed treatment.
Treatment of these various disorders is not unfortunately
standardized due to the rarity of HL-related neurologic
disorders, and consequently, management of these disorders
reﬂects treatment for similar disorders occurring in other
more common cancers.
2. DirectNeurologic Complications of HL
HL is predominantly a disease of the lymph nodes although
extranodal sites of disease may be present in 10% of
cases.Directneurologicdysfunctionresultsfromintracranial
metastases, metastases to the epidural space of the spinal
cord with resultant spinal cord or nerve root compression,
metastaticleptomeningealdisease,andintramedullaryspinal
cord metastases. In a retrospective review of HL, Wood
and coltman reported intracranial metastases in 3% of
patients and epidural spinal cord metastases in 3% of 353
patients with HL [3]. Other series have estimated central
nervous system (CNS) involvement in HL less often (0.5%)
likely reﬂecting improvement in systemic therapy with a
corresponding decrease in metastatic disease [4].2 Advances in Hematology
Direct (metastatic)
Intraparenchymal
Dural
Leptomeningeal
Epidural spinal cord
Indirect
Paraneoplastic
Cerebellar degeneration
Limbic encephalitis
CNS angiitis
Treatment-related
Radiotherapy
Dropped head syndrome
Premature carotid artery atherosclerosis with cardiovascular complications
Brachial plexopathy
Chemotherapy
Cardiomyopathy with CNS emboli and cardiovascular complications
Toxic peripheral neuropathy
Algorithm 1: Neurological complications of Hodgkin’s lymphoma.
2.1.IntracranialHL. MetastaticintracranialHLinvolvement
is rare but well characterized [4]. The majority of cases
are in patients with advanced, refractory disease, although
intracranial disease may occasionally be present at HL
diagnosis [5–7]. In literature review which included 36
patients with intracranial HL, the sites of involvement were
brain parenchyma in 64% (cerebrum 44% and cerebel-
lum/brainstem 20%), dura or leptomeninges in 19%, corpus
callosum in 3%, pituitary in 3%, and unknown/not stated in
12% [7]. The presenting signs and symptoms reﬂect location
of metastases and include cranial nerve palsies (55%),
headaches (36%), weakness (33%), papilledema (19%),
nausea and vomiting (17%), memory problems (17%),
seizures (14%), gait disturbance (5%), and other (3%). Due
to its rarity, treatment for intracranial metastatic HL is
not well established but most often employs fractionated
radiotherapy.
2.2. Epidural HL. Metastases of HL to the spinal epidural
space may cause spinal cord or cauda equina compression
[8–12].TheincidenceofHLcausingspinalcordcompression
has been estimated to be 0.2% [9]. Symptoms of spinal cord
compression (not unique to HL) include back pain (pro-
gressive, worse when lying ﬂat, and improved with walking),
weakness, sensory loss, autonomic dysfunction (painless
urinary retention, fecal incontinence, and impotence), and
ataxia. Signs of spinal cord compression result in sensory
level, paraparesis, hyperreﬂexia, and presence of the Babin-
ski response. Cauda equina compression is characterized
by back pain, dermatomal sensory loss, and asymmetric
paraparesis. Because HL is usually chemosensitive, surgical
decompression may not be necessary and if employed,
may delay the delivery of deﬁnitive chemotherapy. Surgery,
customarily vertebrectomy, is clearly indicated however if
the diagnosis is uncertain or if there is evidence of spinal
instability. Chemotherapy alone or chemotherapy followed
by radiotherapy is eﬀective treatment in the majority of
patients [8, 9, 12].
2.3. Leptomeningeal HL. Cerebrospinal ﬂuid (CSF) dissemi-
nation(leptomeningealmetastases)ofHLsimilartoneoplas-
tic meningitis due to other cancers is characterized by multi-
focal signs and symptoms aﬀecting the brain (headache, gait
diﬃculty,cognitivedysfunction,andseizures),cranialnerves
(diplopia, hearing loss, and facial weakness), and spine and
exiting nerve roots (weakness, sensory loss, and autonomic
dysfunction). HL leptomeningeal metastases is an infrequent
cause of neoplastic meningitis though small cases series
have been reported [13–16]. Magnetic resonance imaging
(MRI) may display focal or diﬀuse contrast enhancement
of the meninges, subarachnoid nodules or intradural exiting
nerve (brain or spinal cord) contrast enhancement or
enlargement. CSF studies often reveal an increased opening
pressure, lymphocytic pleocytosis, increased protein, and/or
hypoglycorrhachia.AuniquefeatureofleptomeningealHLis
that it is often associated with a CSF eosinophilic pleocytosis
[13, 17, 18]. The mechanism of CSF eosinophilia in HL is
unclear as it does not appear to be secondary to absolute
blood eosinophilia [13]. Other diseases associated with
CSF eosinophilia include parasitic diseases (cysticercosis,
trichinosis, and helminth infection), tuberculous meningi-
tis, symptomatic neurosyphilis, subacute sclerosing panen-
cephalitis, and Coxsackie virus infection [19]. Identifying
Reed-Sternberg cells in the CSF is the deﬁnitive diagnostic
test for ascertaining HL-related leptomeningeal metastases
[14, 15]. No standard treatment exists for leptomeningeal
HL,butsimilartoothercausesoflymphomatousmeningitis,
intra-CSF chemotherapy may provide palliation in conjunc-
tion with involved-ﬁeld radiotherapy [13, 20, 21].
2.4. Intramedullary Spinal Cord HL. The spine parenchyma
(intramedullary spine) is a rare site of metastatic disease inAdvances in Hematology 3
patients with HL [22, 23]. Intramedullary spinal metastases
arise from direct hematogenous spread to the parenchyma
of the spinal cord or by centripetal growth of tumor along
spinalnerverootswithsecondaryinvasionofthespinalcord.
Signs and symptoms are similar to those with epidural spinal
cord compression, except back pain may not be prominent.
Chemotherapy and/or radiation therapy are the preferred
treatment options.
3. IndirectNeurologic Complications of HL
3.1.ParaneoplasticSyndromes. Paraneoplasticsyndromesare
disorders of tissue or organ function caused by a cancer
but at a site remote from the cancer or its metastases [24].
Any portion of the nervous system (central or peripheral)
can be aﬀected by a paraneoplastic syndrome. Speciﬁcity
of nervous system paraneoplastic disorders is reﬂected by
involvement of one or several anatomic sites or by nervous
system cell types aﬀected. The majority of paraneoplastic
disorders are thought to be immune-mediated [25]. Most
patients with a paraneoplastic syndrome have antibodies in
their serum or CSF that react with both the nervous system
and the underlying cancer. Although there can be overlap, a
speciﬁc antibody is usually associated with a speciﬁc clinical
syndrome and a restricted subgroup of cancer.
Several paraneoplastic syndromes have been reported in
patients with HL of which cerebellar degeneration is the best
characterized. There is a strong association between the cir-
culating antineuronal antibody anti-Tr with paraneoplastic
cerebellar degeneration and HL [26]. Unlike other parane-
oplastic syndromes in which the paraneoplastic syndrome
precedes the diagnosis of cancer, the paraneoplastic disorder
of HL begins after the diagnosis of HL or when the patient
is in remission [26–28]. In one series of 21 patients, the
majority were young (median age 44 years) men (18/21).
D i a g n o s i so fH Lp r e c e d e dn e u r o l o g i cs y m p t o m sb y1t o
54 months in 17/21 patients and during remission in four
[27]. The typical presentation is pancerebellar dysfunction
(dysarthria, nystagmus, truncal ataxia, and appendicular
ataxia) developing over months. Plasmapheresis, corticos-
teroids, and immunosuppressant medications are of no
apparent beneﬁt. The syndrome may resolve spontaneously
otherwise there appears to be no eﬀective therapy [27, 28].
A separate, distinct paraneoplastic cerebellar degenera-
tion syndrome associated with autoantibodies to a mouse
metabotropic glutamate receptor (mGLuR1) in two patients
with HL has been reported [29]. The patients presented
with subacute cerebellar ataxia several years after successful
treatment for HL. One patient experienced improvement
of their ataxia after treatment with prednisone, intravenous
immunoglobulin, and plasma exchange. A third case of
mGLuR1 paraneoplastic cerebellar degeneration without
history of HL has been described, raising the question
whether the association with HL in the ﬁrst series is
coincidental [30].
Anti-NMDA (N-methyl-D-aspartate) receptor encepha-
litis is a paraneoplastic syndrome characterized by limbic
encephalitis (memory loss, confusion, seizures, and psychi-
atricabnormalities),rhythmicmovementdisorder,hypoven-
tilation requiring ventilation, and autonomic instability,
mostly occurring in women with ovarian teratoma [31].
Zandi reported a patient who presented with anterograde
memory impairment at HL relapse [32]. Antibodies to the
NMDA receptor were identiﬁed in serum and CSF. The
patient improved with aggressive immunotherapy. Several
other cases of paraneoplastic limbic encephalitis without an
identiﬁed autoantibody have been reported in association
with HL [33, 34]. Because the patients presented prior to
the recognition of anti-NMDA-receptor encephalitis, their
NMDA antibody status is unknown.
Cases of acute inﬂammatory demyelinating polyradicu-
lopathy (Guillain-Barre syndrome) occurring in patients un-
dergoing active treatment for HL or at disease recurrence
have been reported. Whether the neurologic syndrome was
associated with HL as a paraneoplastic syndrome, secondary
toanaspectofthetreatment,orcoincidentalisnotclear[35–
38].
Other possible paraneoplastic complications of HL
include chorea and ataxia, subacute sensory neuropathy,
motor neuron disease, myasthenia gravis, stiﬀ person syn-
drome, and brachial neuropathy [39–44].
3.2. Primary Angiitis of the Central Nervous System (PACNS).
PACNS is a noninfectious granulomatous angiitis that aﬀects
small arteries of the leptomeninges, and parenchyma of the
brain and spinal cord in the absence of systemic vasculitis.
Patients present with headache, encephalopathy, seizure,
hemorrhage, and multifocal infarcts [45]. The etiology is
unknown, although there may be an association between
PACNS and HL. The diagnoses of PACNS and HL are
often made simultaneously or closely correlated in time [46–
49]. In addition to arterial involvement, recurrent cerebral
venous thrombosis, despite anticoagulation in a patient
with HL, has been described. The venous thrombosis was
thought to be inﬂammatory in etiology since the patient had
aseptic meningitis and experienced a dramatic response to
rituximab and steroids [50]. Other conditions that have been
associatedwithPACNSincludeherpeszoster,non-Hodgkin’s
lymphoma, human immunodeﬁciency virus, and Sjogren’s
syndrome [49]. Since herpes zoster infections are common
in patients with HL [51], the relationship between zoster
vasculitis and PACNS associated with HL is unclear.
4.Neurologic Complications of HLTreatment
4.1. Neurologic Complications of Radiotherapy for HL. Tra-
ditionally, standard therapy for HL included “mantle ﬁeld”
radiotherapy (RT). The mantle ﬁeld encompasses the sub-
mandibular, cervical, supraclavicular, infraclavicular, axil-
lary, mediastinal, subcarinal, and hilar lymph nodes. Con-
cern regarding the long-term complications of RT has led to
tailored treatment protocols in line with prognostic factors
that allow for reductions in the amount and extent of RT
[52].
4.1.1. Dropped Head Syndrome. The dropped head syn-
drome is characterized by severe weakness of neck extensor4 Advances in Hematology
muscles causing an inability to extend the neck which results
in a posture with the head ﬂexed forward and chin on
chest deformity. An association of dropped head syndrome
with mantle ﬁeld RT was ﬁrst reported by Johansson et al.
[53]. Since then, the “dropped head syndrome” has been
increasingly recognized as a long-term complication of high
dose mantle ﬁeld RT [54–56]. The classical presentation is
severe weakness and atrophy of cervical and shoulder girdle
musculature (splenius capitis, supraspinatus, infraspina-
tus, trapezius, sternocleidomastoid, and deltoid muscles)
leading to the dropped head syndrome. The symptoms
begin many years (most cases occuring >20 years) after
high-dose mantle ﬁeld radiotherapy. Sensory loss, cramps,
paresthesias, fasciculations, and myokymia on EMG are not
present. The weakness may progress over years but does
not extend beyond the initially involved muscle groups. The
pathophysiology of this rare RT complication is unclear.
It is thought to result from a combination of primary
muscle damage and upper cervical anterior horn/nerve
root lesions. Both myopathic and neurogenic EMG changes
have been reported. Muscle biopsy reveals noninﬂammatory
myopathic changes, presence of nemaline rod bodies, or
features of muscle denervation. Treatment is supportive
often employing a cervical collar to maintain the head
upright.
4.1.2. Brachial Plexopathy. Acute brachial plexopathy has
been reported in several HL patients during treatment with
high dose mantle ﬁeld RT [57, 58]. The patients developed
painful, acute brachial plexus dysfunction (shoulder and
arm pain followed by arm/hand sensory loss and lower
motor neuron weakness) within days to weeks of starting RT;
improvement occurred despite continued RT. Clinically, the
syndrome is indistinguishable from acute idiopathic brachial
neuritis. The pathogenesis is unknown, but an immune-
mediated neuropathy precipitated by the radiotherapy has
been postulated [57]. Late-delayed brachial plexus neuropa-
thy following mantle RT has also been reported and like
other cancer-related radiation plexopathies is painless and
associated with myokymia [59].
4.1.3. Episodic Neurologic Dysfunction. Feldmann and Pos-
ner described 14 patients (12 women and two men, 26 to 51
years of age) in remission and without evidence of HL who
presented with episodic and presumed vascular neurologic
dysfunction [60]. All but one received mantle ﬁeld RT. Most
patients experienced visual disturbances including attacks
of “ﬂashing lights” in one or both eyes, monocular visual
loss, or hemianopia. Other episodic neurologic symptoms
included language dysfunction, segmental motor, or seg-
mental sensory defects. Absence of headache argued against
a migrainous phenomenon. The authors speculated that
these episodes represented transient ischemic attacks (TIA);
only one patient was diagnosed with cerebral infarction
at presentation or on followup. The disorder appears to
be benign; nine became asymptomatic (3 spontaneously,
1 patient with carotid stenosis underwent endarterectomy,
and 5 received antiplatelet therapy). Despite the seemingly
benign nature of episodic neurologic phenomena in patients
successfully treated for HL, cerebral infarction may be a
late treatment complication [61]. Patients presenting with
episodic neurologic symptoms should undergo complete
neurologic workup including echocardiography to look for
valvular heart disease and cardiomyopathy, cervical and
aortic angiography, and coagulation studies.
4.1.4. Neurologic Complications of Chemotherapy for HL.
The standard chemotherapy regimen for HL includes dox-
orubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
Doxorubicin causes a cumulative, dose-dependent car-
diomyopathy which can lead to transient ischemic attacks
(TIA) or cerebral infarction from cardiac emboli [62].
Liposomal doxorubicin often causes plantar-palmar ery-
throdysesthesia (hand and foot syndrome) [63]. Bleomycin
may cause cerebral or myocardial infarcts in patients who
were successfully treated for HL [64]. Vinblastine may
cause a predominantly length-dependent small ﬁber sensory
peripheral neuropathy. The mechanism of neuropathy is
thought to be interference of axonal transport due to
tubulin binding. The major site of damage is thought to
be the dorsal root ganglion which lies outside the blood-
nerve barrier [65]. Dacarbazine in isolation rarely causes
neurologic dysfunction.
Mechlorethamine, vincristine, procarbazine, and pred-
nisone (MOPP) is another chemotherapy regimen that has
been used for HL. Mechlorethamine is rarely neurotoxic, but
encephalopathy and hearing loss have been reported after
standardinfusion[66,67].Vincristineisthemostneurotoxic
vinca alkaloid; it causes a dose limiting mixed motor-sensory
neuropathy in the majority of patients [68]. The earliest
complaint is tingling and paresthesias in the ﬁngertips and
later the toes [65]. Fine motor movements of the ﬁngers
and toes are often impaired. Loss of Achilles reﬂexes is the
earliest ﬁnding on examination. With continued treatment,
other deep tendon reﬂexes disappear. Objective sensory loss
is uncommon early but with progression clinical ﬁndings
becomes evident and involves the classic glove and stocking
distribution. Patients often experience weakness of extensor
muscles particularly in the feet. The symptoms usually
develop a few weeks following initiation of therapy and
progress for several weeks after drug discontinuance. Symp-
toms are usually reversible once treatment is discontinued
if treatment is interrupted early and before clinical signs
are manifest. Neurophysiologic studies are consistent with
an axonal neuropathy. In addition to peripheral neuropathy,
vincristine causes mononeuropathies involving peripheral
or cranial nerves and autonomic dysfunction. Dysfunc-
tion of the oculomotor nerve, recurrent laryngeal nerve,
facial nerve, acoustic nerve, and optic nerve have been
described [65]. Autonomic dysfunction includes constipa-
tion, paralytic ileus, bladder atony, impotence, and postural
hypotension.Procarbazineisrarelyneurotoxicbutmaycause
encephalopathy and reversible peripheral neuropathy [65].
5. Conclusions
Because HL aﬀects both the central and peripheral nervous
systems, HL may present in a pleomorphic manner andAdvances in Hematology 5
mimic a variety of neurologic syndromes. HL is associated
with a myriad of neurological complications that occur
both as a direct consequence of HL (intraparenchymal brain
metastases, epidural spinal cord compression, HL meningi-
tis, and dural metastases) and indirectly due to treatment
or paraneoplastic disorders. The majority of nervous system
complications of HL are metastatic or treatment related in
etiology (Algorithm 1). Metastatic complications are treated
in a manner similar to other cancers with comparable
metastatic syndromes. Peripheral nervous system disor-
ders are nearly always treatmentrelated (radiation-induced
brachial plexopathy or dropped head syndrome and vinca
alkaloid-inducedperipheralneuropathy)andrespondbestto
discontinuance of the neurotoxic agent and supportive care.
Familiarity with the various neurologic disorders related to
HL is critical to make the correct diagnosis and institute the
appropriate treatment.
References
[1] B. Schnitzer, “Hodgkin Lymphoma,” Hematology/Oncology
Clinics of North America, vol. 23, no. 4, pp. 747–768, 2009.
[ 2 ]T .A .L i s t e r ,D .C r o w t h e r ,S .B .S u t c l i ﬀee ta l . ,“ R e p o r to fa
committee convened to discuss the evaluation and staging of
patients with Hodgkin’s disease: cotswolds meeting,” Journal
of Clinical Oncology, vol. 7, no. 11, pp. 1630–1636, 1989.
[3] N.L.WoodandC.A.Coltman,“Localizedprimaryextranodal
Hodgkin’s disease,” Annals of Internal Medicine, vol. 78, no. 1,
pp. 113–118, 1973.
[4] M. D. Sapozink and H. S. Kaplan, “Intracranial Hodgkin’s
disease. A report of 12 cases and review of the literature,”
Cancer, vol. 52, no. 7, pp. 1301–1307, 1983.
[5] R. Vera Jr., R. Enriquez, and R. Papac, “Hodgkin’s disease,
intracranial involvement. Report of a case and review of the
literature,” American Journal of Clinical Oncology, vol. 8, no. 1,
pp. 73–76, 1985.
[6] G. A. Young, “Lymphoma at uncommon sites,” Journal of
Hematology & Oncology, vol. 17, no. 2, pp. 53–83, 1999.
[7] K. Hirmiz, A. Foyle, D. Wilke et al., “Intracranial presentation
of systemic Hodgkin’s disease,” Leukemia and Lymphoma, vol.
45, no. 8, pp. 1667–1671, 2004.
[8] P. A. Burch and S. A. Grossman, “Treatment of epidural cord
compressions from Hodgkin’s disease with chemotherapy.
A report of two cases and a review of the literature,” The
AmericanJournalofMedicine,vol.84,no.3,pp.555–558,1988.
[9] S. A. Higgins and R. E. Peschel, “Hodgkin’s disease with spinal
cord compression: a case report and a review of the literature,”
in Cancer, vol. 75, no. 1, pp. 94–98, 1995.
[10] J. S. Citow, B. Rini, R. Wollmann, and R. L. Macdonald,
“Isolated, primary extranodal Hodgkin’s disease of the spine:
case report,” Neurosurgery, vol. 49, no. 2, pp. 453–457, 2001.
[11] L. Riﬀaud, M. Adn, G. Brassier, and X. Morandi, “Acute
cauda equina compression revealing Hodgkin’s disease: a case
report,” Spine, vol. 28, no. 14, pp. E270–E272, 2003.
[12] V. Gupta, A. Srivastava, and B. Bhatia, “Hodgkin disease
with spinal cord compression,” Journal of Pediatric Hematol-
ogy/Oncology, vol. 31, no. 10, pp. 771–773, 2009.
[ 1 3 ]D .H o l l i s t e rJ r . ,M .C l e m e n t s ,M .C o l e m a n ,a n dF .P e t i t o ,
“EosinophilicmeningitisinHodgkin’sdisease.Reportofacase
and review of the literature,” Archives of Internal Medicine, vol.
143, no. 3, pp. 590–592, 1983.
[14] U. A. Shenoy, J. P. Kushner, and G. B. Schumann, “Cytologic
diagnosis and monitoring of Hodgkin’s disease in cere-
brospinal ﬂuid: a case report,” Diagnostic Cytopathology, vol.
3, no. 4, pp. 323–325, 1987.
[15] L. A. Perez-Jaﬀe, K. E. Salhany, R. J. Green, T. Griﬃn,
E. A. Stadtmauer, and P. K. Gupta, “Cerebral spinal ﬂuid
involvement by Hodgkin’s disease diagnosed by CSF cytology
and immunocytochemistry,” Diagnostic Cytopathology, vol.
20, no. 4, pp. 219–223, 1999.
[16] M. U.S. Sachdeva, V. Suri, P. Malhotra, and R. Srinivasan,
“CerebrospinalﬂuidinﬁltrationinHodgkinlymphoma:acase
report,” Acta Cytologica, vol. 52, no. 5, pp. 623–626, 2008.
[17] D. R. Strayer and R. A. Bender, “Eosinophilic meningitis
complicating Hodgkin’s disease. A report of a case and review
of the literature,” Cancer, vol. 40, no. 1, pp. 406–409, 1977.
[18] R. Patchell and M. C. Perry, “Eosinophilic meningitis in
Hodgkin disease,” Neurology, vol. 31, no. 7, pp. 887–888, 1981.
[19] R. A. Fishman, Cerebrospinal Fluid in Diseases of the Nervous
System, Saunders, Philadelphia, Pa, USA, 1992.
[20] M. J. Mulligan, R. Vasu, C. E. Grossi et al., “Case report: neo-
plastic meningitis with eosinophilic pleocytosis in Hodgkin’s
disease: a case with cerebellar dysfunction and a review of the
literature,” American Journal of the Medical Sciences, vol. 296,
no. 5, pp. 322–326, 1988.
[21] A. P. Anselmo, A. Proia, C. Cartoni et al., “Meningeal
localization in a patient with Hodgkin’s disease. Description
of a case and review of the literature,” Annals of Oncology, vol.
7, no. 10, pp. 1071–1075, 1996.
[22] J. M. Lyding, A. Tseng, and A. Newman, “Intramedullary
spinal cord metastasis in Hodgkin’s disease: rapid diagnosis
and treatment resulting in neurologic recovery,” Cancer, vol.
60, no. 8, pp. 1741–1744, 1987.
[23] F. Jardin, A. Stamatoullas, C. Fruchart, J. D’Anjou, J. F.
Cl´ ement, and H. Tilly, “Atteinte de la moelle epiniere et
envahissement meninge lors d’une maladie de Hodgkin. A
propos d’un cas et revue de la litterature,” R e v u ed eM e d e c i n e
Interne, vol. 20, no. 3, pp. 267–271, 1999.
[24] J. B. Posner and J. O. Dalmau, “Paraneoplastic syndromes
of the nervous system,” Clinical Chemistry and Laboratory
Medicine, vol. 38, no. 2, pp. 117–122, 2000.
[25] R. B. Darnell and J. B. Posner, “Paraneoplastic syndromes
involving the nervous system,” The New England Journal of
Medicine, vol. 349, no. 16, pp. 1543–1554, 2003.
[26] F. Bernal, S. Shams’Ili, I. Rojas et al., “Anti-Tr antibodies
as markers of paraneoplastic cerebellar degeneration and
Hodgkin’s disease,” Neurology, vol. 60, no. 2, pp. 230–234,
2003.
[27] J. Hammack, H. Kotanides, M. K. Rosenblum, and J. B.
Posner, “Paraneoplastic cerebellar degeneration. II. Clinical
and immunologic ﬁndings in 21 patients with Hodgkin’s
disease,” Neurology, vol. 42, no. 10, pp. 1938–1943, 1992.
[28] J. Peltola, A. Hietaharju, I. Rantala, T. Lehtinen, and H. Haa-
pasalo, “A reversible neuronal antibody (anti-Tr) associated
paraneoplastic cerebellar degeneration in Hodgkin’s disease,”
Acta Neurologica Scandinavica, vol. 98, no. 5, pp. 360–363,
1998.
[29] P.SillevisSmitt,A.Kinoshita,B.DeLeeuwetal.,“Paraneoplas-
tic cerebellar ataxia due to autoantibodies against a glutamate
receptor,” The New England Journal of Medicine, vol. 342, no.
1, pp. 21–27, 2000.
[30] R. Marignier, F. Chenevier, V. Rogemond et al., “Metabotropic
glutamatereceptortype1autoantibody-associatedcerebellitis:
aprimaryautoimmunedisease?”ArchivesofNeurology,vol.67,
no. 5, pp. 627–630, 2010.6 Advances in Hematology
[31] J. Dalmau, E. T¨ uz¨ un, H.-Y. Wu et al., “Paraneoplastic anti-
N-methyl-D-aspartate receptor encephalitis associated with
ovarian teratoma,” Annals of Neurology, vol. 61, no. 1, pp. 25–
36, 2007.
[32] M. S. Zandi, S. R. Irani, G. Follows, A. M. Moody, P.
Molyneux, and A. Vincent, “Limbic encephalitis associated
with antibodies to the nmda receptor in hodgkin lymphoma,”
Neurology, vol. 73, no. 23, pp. 2039–2040, 2009.
[33] S. H. Gultekin, M. R. Rosenfeld, R. Voltz, J. Eichen, J. B.
Posner, and J. Dalmau, “Paraneoplastic limbic encephalitis:
neurological symptoms, immunological ﬁndings and tumour
association in 50 patients,” Brain, vol. 123, no. 7, pp. 1481–
1494, 2000.
[34] D. Olmos, A. Rueda, J. M. Jurado, and E. Alba, “Presentation
of Hodgkin’s lymphoma with ophelia syndrome,” Journal of
Clinical Oncology, vol. 25, no. 13, pp. 1802–1803, 2007.
[35] R. P. Lisak, M. Mitchell, B. Zweiman, E. Orrechio, and A.
K. Asbury, “Guillain-Barr´ e syndrome and Hodgkin’s disease:
three cases with immunological studies,” Annals of Neurology,
vol. 1, no. 1, pp. 72–78, 1977.
[36] J.CuttnerandR.Meyer,“Guillain-Barresyndromeinapatient
with Hodgkin’s disease,” Mount Sinai Journal of Medicine, vol.
45, no. 3, pp. 415–417, 1978.
[ 3 7 ]J .J u l i e n ,C .V i t a l ,G .A u p y ,A .L a g u e m y ,D .D a r r i e t ,a n d
C. Brechenmacher, “Guillain-Barre syndrome and Hodgkin’s
disease–ultrastructural study of a peripheral nerve,” Journal of
the Neurological Sciences, vol. 45, no. 1, pp. 23–27, 1980.
[38] D. E. Amundson and J. C. Goodman, “Hodgkin’s disease in
associationwithGuillain-Barre-Strohlsyndrome:casereport,”
Military Medicine, vol. 148, no. 2, pp. 512–513, 1983.
[ 3 9 ]D .H .L a c h a n c e ,B .P .O ’ N e i l l ,C .M .H a r p e rJ r . ,P .M .B a n k s ,
and T. L. Cascino, “Paraneoplastic brachial plexopathy in a
patient with Hodgkin’s disease,” Mayo Clinic Proceedings, vol.
66, no. 1, pp. 97–101, 1991.
[40] V. Plante-Bordeneuve, M. Baudrimont, N. C. Gorin, and R.
K. Gherardi, “Subacute sensory neuropathy associated with
Hodgkin’s disease,” Journal of the Neurological Sciences, vol.
121, no. 2, pp. 155–158, 1994.
[41] S. Deodhare, P. O’Connor, D. Ghazarian, and J. M. Bilbao,
“Paraneoplastic limbic encephalitis in Hodgkin’s disease,” The
Canadian Journal of Neurological Sciences, vol. 23, no. 2, pp.
138–140, 1996.
[42] T. T. Batchelor, M. Platten, D. E. Palmer-Toy et al., “Chorea as
a paraneoplastic complication of Hodgkin’s disease,” Journal
of Neuro-Oncology, vol. 36, no. 2, pp. 185–190, 1998.
[43] I. Maslovsky, L. Volchek, R. Blumental, A. Ducach, and G.
Lugassy, “Persistent paraneoplastic neurologic syndrome after
successful therapy of Hodgkin’s disease,” European Journal of
Haematology, vol. 66, no. 1, pp. 63–65, 2001.
[44] B. Gutmann, C. Crivellaro, M. Mitterer, H. Zingerle, E.
Egarter-Vigl, and C. J. Wiedermann, “Paraneoplastic stiﬀ-
person syndrome, heterotopic soft tissue ossiﬁcation and
gonarthritis in a HLA B27-positive woman preceding the
diagnosis of Hodgkin’s lymphoma,” Haematologica, vol. 91,
supplement 12, ECR59, 2006.
[45] J. Birnbaum and D. B. Hellmann, “Primary angiitis of the
central nervous system,” Archives of Neurology, vol. 66, no. 6,
pp. 704–709, 2009.
[ 4 6 ]M .J o h n s o n ,R .M a c i u n a s ,P .D u t t ,M .E .C l i n t o n ,a n dR .
Collins, “Granulomatous angiitis masquerading as a mass
lesion. Magnetic resonance imaging and stereotactic biopsy
ﬁndings in a patient with occult Hodgkin’s disease,” Surgical
Neurology, vol. 31, no. 1, pp. 49–53, 1989.
[ 4 7 ]D .J .I n w a r d s ,D .G .P i e p g r a s ,J .T .L i e ,B .P .O ’ N e i l l ,B .W .
Scheithauer, and T. M. Habermann, “Granulomatous angiitis
of the spinal cord associated with Hodgkin’s disease,” Cancer,
vol. 68, no. 6, pp. 1318–1322, 1991.
[48] R. W.S. Yuen and P. C. Johnson, “Primary angiitis of the
central nervous system associated with Hodgkin’s disease,”
Archives of Pathology and Laboratory Medicine, vol. 120, no. 6,
pp. 573–576, 1996.
[49] C. L. Rosen, L. DePalma, and A. Morita, “Primary angiitis
of the central nervous system as a ﬁrst presentation in
Hodgkin’s disease: a case report and review of the literature,”
Neurosurgery, vol. 46, no. 6, pp. 1504–1510, 2000.
[50] S. Roggerone, A. Traverse-Glehen, L. Derex et al., “Recurrent
cerebral venous thrombosis revealing paraneoplastic angiitis
in Hodgkin’s lymphoma,” J o u r n a lo fN e u r o - O n c o l o g y , vol. 89,
no. 2, pp. 195–198, 2008.
[51] V. F. Guinee, J. J. Guido, and K. A. Pfalzgraf, “The incidence of
herpeszosterinpatientswithHodgkin’sdisease.Ananalysisof
prognostic factors,” Cancer, vol. 56, no. 3, pp. 642–648, 1985.
[52] C. Ferm´ e, H. Eghbali, J. H. Meerwaldt et al., “Chemotherapy
plus involved-ﬁeld radiation in early-stage Hodgkin’s disease,”
The New England Journal of Medicine, vol. 357, no. 19, pp.
1916–1927, 2007.
[53] A.-S. Johansson, M. Erlanson, P. Lenner, J. Lindh, and B.
Osterman, “Ofta sena biverkningar av hodgkinbehandling:
muskelatroﬁ f¨ orbisedd risk efter radioterapi,” Lakartidningen,
no. 1-2, pp. 44–47, 1998.
[54] A. Furby, A. B´ ehin, J.-P. Lefaucheur et al., “Late-onset cervi-
coscapular muscle atrophy and weakness after radiotherapy
for Hodgkin disease: a case series,” Journal of Neurology,
Neurosurgery and Psychiatry, vol. 81, no. 1, pp. 101–104, 2010.
[ 5 5 ]C .S .P o r t l o c k ,P .B o l a n d ,A .P .H a y s ,C .R .A n t o n e s c u ,
and M. K. Rosenblum, “Nemaline myopathy: a possible late
complicationofHodgkin’sdiseasetherapy,”HumanPathology,
vol. 34, no. 8, pp. 816–818, 2003.
[56] J. Rowin, G. Cheng, S. L. Lewis, and M. N. Meriggioli, “Late
appearance of dropped head syndrome after radiotherapy for
Hodgkin’s disease,” Muscle and Nerve, vol. 34, no. 5, pp. 666–
669, 2006.
[57] B. A. Malow and D. M. Dawson, “Neuralgic amyotrophy
in association with radiation therapy for Hodgkin’s disease,”
Neurology, vol. 41, no. 3, pp. 440–441, 1991.
[58] M. Churn, V. Clough, and A. Slater, “Early onset of bilateral
brachialplexopathyduringmantleradiotherapyforHodgkin’s
disease,” Clinical Oncology, vol. 12, no. 5, pp. 289–291, 2000.
[59] N. J. Wadd and H. H. Lucraft, “Brachial plexus neuropathy
following mantle radiotherapy,” Clinical Oncology, vol. 10, no.
6, pp. 399–400, 1998.
[60] E. Feldmann and J. B. Posner, “Episodic neurologic dysfunc-
tion in patients with Hodgkin’s disease,” Archives of Neurology,
vol. 43, no. 12, pp. 1227–1233, 1986.
[61] D. C. Bowers, D. E. McNeil, Y. Liu et al., “Stroke as a
late treatment eﬀect of Hodgkin’s disease: a report from
the Childhood Cancer Survivor Study,” Journal of Clinical
Oncology, vol. 23, no. 27, pp. 6508–6515, 2005.
[62] S. Schachter and R. Freeman, “Transient ischemic attack and
adriamycin cardiomyopathy,” Neurology, vol. 32, no. 12, pp.
1380–1381, 1982.
[63] D. Lorusso, A. Di Stefano, V. Carone, A. Fagotti, S. Pisconti,
and G. Scambia, “Pegylated liposomal doxorubicin-related
palmar-plantar erythrodysesthesia (’hand-foot’ syndrome),”
Annals of Oncology, vol. 18, no. 7, pp. 1159–1164, 2007.Advances in Hematology 7
[64] N. Shahab, S. Haider, and D. C. Doll, “Vascular toxicity of
antineoplasticagents,”SeminarsinOncology,vol.33,no.1,pp.
121–138, 2006.
[65] L. M. DeAngelis and J. B. Posner, Neurologic Complications of
Cancer, Oxford University Press, New York, NY, USA, 2009.
[66] N. C. Bethlenfalvay and J. J. Bergin, “Severe cerebral toxicity
after intravenous nitrogen mustard therapy,” Cancer, vol. 29,
no. 2, pp. 366–369, 1972.
[67] G. M. Segal and L. G. Duckert, “Reversible mechlorethamine-
associated hearing loss in a patient with Hodgkin’s disease,”
Cancer, vol. 57, no. 6, pp. 1089–1091, 1986.
[68] J. K. Sul and L. M. DeAngelis, “Neurologic complications of
cancer chemotherapy,” Seminars in Oncology, vol. 33, no. 3,
pp. 324–332, 2006.